Researcher explains status of Depo Provera.  [Answer to question of Marienetta Blackwell].
D000569:Americas; D001695:Biology; D001943:Breast Neoplasms; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003376:Counseling; D003695:Delivery of Health Care; D019049:Developed Countries; D004194:Disease; D004703:Endocrine System; D004967:Estrogens; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D006285:Health Planning; D006297:Health Services Accessibility; D006728:Hormones; D007267:Injections; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms; D009656:North America; D009934:Organization and Administration; D010820:Physicians; D010827:Physiology; D011057:Politics; D014481:United States
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D004967:Estrogens; D006728:Hormones; D017258:Medroxyprogesterone Acetate
Americas; Biology; Breast Cancer; Cancer; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Availability; Contraceptive Effectiveness; Counseling; Depo-provera--side effects; Developed Countries; Diseases; Distributional Activities; Endocrine System; Estrogens; Family Planning; Hormones; Injectables; Medroxyprogesterone Acetate--side effects; Neoplasms; North America; Northern America; Organization And Administration; Physicians; Physiology; Political Factors; Program Activities; Programs; United States; Use-effectiveness